Keyword: Black Diamond Therapeutics

Black Diamond grabs trio of new R&D execs

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up its research work.

Black Diamond Therapeutics

Versant Ventures launched Black Diamond in December 2018 with $20 million to go after an overlooked group of oncogenes, or mutated forms of genes that can drive cancer. A month later, the company picked up another $85 million to move its lead program into the clinic in early 2020.